Home›Silodosin

Silodosin

Also known as: Rapaflo

alpha-Adrenergic BlockerAdrenergic alpha-Antagonists

Route: Oral

11 interactions on record

Silodosin has 11 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Alpha-Blockers, Cyclosporine, Itraconazole. Patients taking Silodosin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 11
Contraindicated: 5
Major: 2
Moderate: 3
Minor: 1

Contraindicated (5)

Silodosin + Alpha-Blockers— Pharmacodynamic interactions may be expected. Silodosin should not be used in combination with other alpha-blockers.
Silodosin + Cyclosporine— Strong P-glycoprotein inhibitor that may increase plasma silodosin concentration. Concomitant use is not recommended.
Silodosin + Itraconazole— Strong CYP3A4 inhibitor that may cause significant increase in silodosin plasma concentrations. Concomitant administrati…
Silodosin + Ketoconazole— Strong CYP3A4 inhibitor causing 3.8-fold increase in silodosin maximum plasma concentrations and 3.2-fold increase in ex…
Silodosin + Ritonavir— Strong CYP3A4 inhibitor that may cause significant increase in silodosin plasma concentrations. Concomitant administrati…

Major (2)

Silodosin + Sildenafil— PDE5 inhibitor that with silodosin can cause symptomatic hypotension with increased positive orthostatic test results.
Silodosin + Tadalafil— PDE5 inhibitor that with silodosin can cause symptomatic hypotension with increased positive orthostatic test results.

Moderate (3)

Silodosin + Diltiazem— Moderate CYP3A4 inhibitor that may increase silodosin concentration. Monitor patients for adverse events.
Silodosin + Erythromycin— Concomitant administration with moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) may increase conce…
Silodosin + Verapamil— Moderate CYP3A4 inhibitor that may increase silodosin concentration. Monitor patients for adverse events.

Minor (1)

Silodosin + Digoxin— Concomitant administration did not significantly alter the steady state pharmacokinetics of digoxin. No dose adjustment …

Silodosin + Alpha-Blockers⛔Contraindicated

Pharmacodynamic interactions may be expected. Silodosin should not be used in combination with other alpha-blockers.

Silodosin + Cyclosporine⛔Contraindicated

Strong P-glycoprotein inhibitor that may increase plasma silodosin concentration. Concomitant use is not recommended.

Silodosin + Itraconazole⛔Contraindicated

Strong CYP3A4 inhibitor that may cause significant increase in silodosin plasma concentrations. Concomitant administration is contraindicated.

Silodosin + Ketoconazole⛔Contraindicated

Strong CYP3A4 inhibitor causing 3.8-fold increase in silodosin maximum plasma concentrations and 3.2-fold increase in exposure. Concomitant administration is contraindicated.

Silodosin + Ritonavir⛔Contraindicated

Strong CYP3A4 inhibitor that may cause significant increase in silodosin plasma concentrations. Concomitant administration is contraindicated.

Silodosin + Sildenafil⚠️Major

PDE5 inhibitor that with silodosin can cause symptomatic hypotension with increased positive orthostatic test results.

Silodosin + Tadalafil⚠️Major

PDE5 inhibitor that with silodosin can cause symptomatic hypotension with increased positive orthostatic test results.

Silodosin + Diltiazem🟡Moderate

Moderate CYP3A4 inhibitor that may increase silodosin concentration. Monitor patients for adverse events.

Silodosin + Erythromycin🟡Moderate

Concomitant administration with moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) may increase concentration of silodosin capsules.

Silodosin + Verapamil🟡Moderate

Moderate CYP3A4 inhibitor that may increase silodosin concentration. Monitor patients for adverse events.

Silodosin + Digoxin🟢Minor

Concomitant administration did not significantly alter the steady state pharmacokinetics of digoxin. No dose adjustment required.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.